Resistin, a Multipotential Therapeutic Target

Q3 Biochemistry, Genetics and Molecular Biology

Biointerface Research in Applied Chemistry Pub Date : 2022-10-31 DOI:10.33263/briac134.384

J. L. Vique‐Sánchez

{"title":"Resistin, a Multipotential Therapeutic Target","authors":"J. L. Vique‐Sánchez","doi":"10.33263/briac134.384","DOIUrl":null,"url":null,"abstract":"Being overweight and obese are risk factors that have increased during the COVID-19 pandemic; these factors increase the white adipose tissue (WAT) that increases the release of adipokines (adiponectin, leptin, and resistin). So, obesity provokes the expansion of adipose tissue; it induces changes in their macrophages of pro-inflammatory cytokines (M2 to M1). These changes increase the resistin levels with effects on the metabolism, inflammation process, glucose homeostasis, and insulin resistance, promote cell proliferation and migration, and even serve as a biomarker for tumorigenesis. Therefore, resistin is proposed as a multipotential therapeutic target to treat different diseases, between chronic-degenerative and some types of cancer, because resistin has characteristics that give it a high probability to be a therapeutic target to attend to and prevent various diseases. In different ways, developing new drugs by molecular docking to use molecules with pharmacological characteristics capable of interacting in the regions of resistin to hinder/block the interaction between resistin and their receptors (Δ-DCN, TLR4, and CAP-1) and by promoting health to reduce overweight and obesity, and this could generate lower plasma serum resistin values, so this review remarks the potential of resistin as multipotential therapeutic target.","PeriodicalId":9026,"journal":{"name":"Biointerface Research in Applied Chemistry","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biointerface Research in Applied Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33263/briac134.384","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Being overweight and obese are risk factors that have increased during the COVID-19 pandemic; these factors increase the white adipose tissue (WAT) that increases the release of adipokines (adiponectin, leptin, and resistin). So, obesity provokes the expansion of adipose tissue; it induces changes in their macrophages of pro-inflammatory cytokines (M2 to M1). These changes increase the resistin levels with effects on the metabolism, inflammation process, glucose homeostasis, and insulin resistance, promote cell proliferation and migration, and even serve as a biomarker for tumorigenesis. Therefore, resistin is proposed as a multipotential therapeutic target to treat different diseases, between chronic-degenerative and some types of cancer, because resistin has characteristics that give it a high probability to be a therapeutic target to attend to and prevent various diseases. In different ways, developing new drugs by molecular docking to use molecules with pharmacological characteristics capable of interacting in the regions of resistin to hinder/block the interaction between resistin and their receptors (Δ-DCN, TLR4, and CAP-1) and by promoting health to reduce overweight and obesity, and this could generate lower plasma serum resistin values, so this review remarks the potential of resistin as multipotential therapeutic target.

查看原文本刊更多论文

抵抗素，一个多潜能治疗靶点

超重和肥胖是新冠肺炎大流行期间增加的风险因素；这些因素增加了白色脂肪组织（WAT），从而增加了脂肪因子（脂联素、瘦素和抵抗素）的释放。因此，肥胖会导致脂肪组织膨胀；它诱导其巨噬细胞中促炎细胞因子（M2至M1）的变化。这些变化增加抵抗素水平，影响新陈代谢、炎症过程、葡萄糖稳态和胰岛素抵抗，促进细胞增殖和迁移，甚至作为肿瘤发生的生物标志物。因此，抵抗素被提议作为治疗慢性变性和某些类型癌症之间的不同疾病的多潜能治疗靶点，因为抵抗素具有高概率成为治疗和预防各种疾病的治疗靶点的特征。以不同的方式，通过分子对接开发新药，使用具有药理学特征的分子，能够在抵抗素区域相互作用，以阻碍/阻断抵抗素与其受体（Δ-DCN、TLR4和CAP-1）之间的相互作用，并通过促进健康来减少超重和肥胖，这可以产生较低的血浆抵抗素值，因此，本文对抵抗素作为多潜能治疗靶点的潜力进行了综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biointerface Research in Applied Chemistry CHEMISTRY, APPLIED-

CiteScore

4.80

自引率

0.00%

发文量

256

期刊介绍： Biointerface Research in Applied Chemistry is an international and interdisciplinary research journal that focuses on all aspects of nanoscience, bioscience and applied chemistry. Submissions are solicited in all topical areas, ranging from basic aspects of the science materials to practical applications of such materials. With 6 issues per year, the first one published on the 15th of February of 2011, Biointerface Research in Applied Chemistry is an open-access journal, making all research results freely available online. The aim is to publish original papers, short communications as well as review papers highlighting interdisciplinary research, the potential applications of the molecules and materials in the bio-field. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.